Merck officer sells 15,000 shares at $121.87

Merck & Co., Inc. President, U.S. Market, Johannes Jacobus Oosthuizen reported selling 15,000 shares of Merck common stock on February 6, 2026 at a weighted average price of $121.8661 per share.

Accepted by SEC EDGAR 02/06/2026 - 04:15 PM EST Learn about SEC filing dates

Rhea-AI Filing Summary

Merck & Co., Inc. President, U.S. Market, Johannes Jacobus Oosthuizen reported selling 15,000 shares of Merck common stock on February 6, 2026 at a weighted average price of $121.8661 per share. The sale occurred in multiple trades between $121.8200 and $121.9500. After this transaction, he directly beneficially owned 21,197.389 Merck shares.

Insider Trade Summary

Net Seller: 15,000 shares

Net Sell 1 txn

Insider Oosthuizen Johannes Jacobus

Role President, U.S. Market

Sold 15,000 shs ($1.83M)

Share of Position Sold 41.4%

Type	Security	Shares	Price	Value
Sale	Common Stock	15,000	$121.8661	$1.83M

Holdings After Transaction: Common Stock — 21,197.389 shares (Direct)

Holdings Before and After: Common Stock, 36,197.389 to 21,197.389 shares (Direct)

Other Insiders: 7 other insiders reported open-market sales of this stock in the 30 days up to this filing.

Footnotes (1)

1. F1. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $121.8200 to $121.9500, inclusive. The reporting person undertakes to provide to Merck & Co., Inc., any security holder of Merck & Co., Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above in this footnote.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did Merck (MRK) report for Johannes Oosthuizen?

Merck reported that Johannes Jacobus Oosthuizen, President, U.S. Market, sold 15,000 shares of Merck common stock on February 6, 2026. The transaction was reported on a Form 4 insider filing under Section 16 of the Securities Exchange Act.

At what price did Johannes Oosthuizen sell Merck (MRK) shares?

Johannes Oosthuizen sold 15,000 Merck shares at a weighted average price of $121.8661 per share. The trades occurred in multiple transactions, with prices ranging from $121.8200 to $121.9500, according to the Form 4 disclosure footnote.

How many Merck (MRK) shares does Johannes Oosthuizen own after the sale?

After the reported sale, Johannes Oosthuizen beneficially owned 21,197.389 shares of Merck common stock. The Form 4 indicates that these shares are held directly, reflecting his remaining equity stake following the 15,000-share disposition.

What is Johannes Oosthuizen’s role at Merck (MRK) in this Form 4?

In this Form 4, Johannes Jacobus Oosthuizen is identified as an officer of Merck, serving as President, U.S. Market. He is not listed as a director or 10% owner, but as a reporting person subject to Section 16 insider reporting rules.

Was the Merck (MRK) insider transaction a purchase or a sale?

The Form 4 shows a sale transaction. Transaction code “S” indicates that Johannes Oosthuizen disposed of 15,000 shares of Merck common stock, reducing his direct holdings while leaving him with 21,197.389 shares after the trades.

How were the Merck (MRK) insider sale prices disclosed on the Form 4?

The filing reports a single weighted average price of $121.8661 for the 15,000 shares sold. A footnote explains the shares were sold in multiple trades between $121.8200 and $121.9500, and offers detailed trade data upon request.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Oosthuizen Johannes Jacobus

(Last) (First) (Middle)

MERCK & CO., INC.

126 EAST LINCOLN AVENUE

(Street)

RAHWAY NJ 07065

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Merck & Co., Inc. [ MRK ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	President, U.S. Market

3. Date of Earliest Transaction (Month/Day/Year)
02/06/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	02/06/2026		S		15,000	D	$121.8661(1)	21,197.389	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $121.8200 to $121.9500, inclusive. The reporting person undertakes to provide to Merck & Co., Inc., any security holder of Merck & Co., Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above in this footnote.

	/s/ Kelly E. W. Grez, as attorney-in-fact for Johannes Oosthuizen	02/06/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.